Loss of SMAD4 suggests impairment of the TGF-β-mediated growth inhibitory pathway, potentially accelerating oncogenesis; notably, the loss rate of SMAD4 was relatively high (75%) in villous adenoma patients. Here, TGFB1 is linked to villous adenoma.